What were the main drivers of Abbott's sales growth in the first quarter of 2004?

Sales growth was primarily driven by strong performance in the Pharmaceutical Products and International segments. Unit growth and favorable foreign exchange rates, particularly the weaker U.S. dollar, also contributed significantly to the increase in net sales and international sales.

What is the significance of the upcoming spin-off of Hospira, Inc.?

The spin-off of Abbott's core hospital products business into Hospira, Inc. (expected April 30, 2004) will create a separate, publicly traded company focused on hospital products. This move is intended to allow Abbott to focus on its core pharmaceutical, diagnostic, and nutritional businesses, while Hospira will operate as an independent entity. Abbott shareholders will receive shares in Hospira as a special dividend. Hospira's pro forma 2003 net sales were approximately $2.4 billion.

How did Abbott's acquisitions impact its financial results?

Abbott acquired i-STAT Corporation in January 2004 for approximately $394 million, which included a $60 million charge for acquired in-process R&D and significant intangible assets and goodwill. The subsequent acquisition of TheraSense, Inc. for $1.2 billion in April 2004 was funded by long-term debt issued in Q1 2004. These acquisitions are expected to strengthen Abbott's position in the diagnostics and diabetes care markets, respectively.

What is the company's stance on its ongoing litigation?

Abbott is involved in several significant legal proceedings, including antitrust suits related to pharmaceutical pricing and marketing practices (e.g., Lupron, Medicare/Medicaid pricing) and patent litigation (e.g., Depakote, Clarithromycin). While reserves of approximately $135 million have been recorded for these matters, management believes that the ultimate disposition of these proceedings should not have a material adverse effect on the company's financial position, cash flows, or results of operations.

ABT 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported strong first-quarter 2004 results, with net sales increasing by 13.9% to $5.22 billion and net earnings rising to $822.9 million, or $0.52 per diluted share. This performance was driven by robust growth across its Pharmaceutical Products and International segments, bolstered by favorable foreign exchange rates. The company also made significant strategic moves, including the acquisition of i-STAT Corporation and the impending spin-off of its hospital products business into a new entity, Hospira, Inc. Operationally, the company saw an increase in operating earnings to $1.03 billion, despite higher R&D and SG&A expenses, reflecting investments in pipeline programs and product launches like Humira. The balance sheet strengthened with increased working capital and a significant increase in cash and cash equivalents. Investors should note the pending spin-off of Hospira, which is expected to be completed by April 30, 2004, and the ongoing litigation related to pricing and marketing practices, though management believes these will not materially impact the company's financial position.

Key Highlights

1Net sales grew 13.9% to $5.22 billion in Q1 2004 compared to Q1 2003.
2Net earnings increased to $822.9 million, or $0.52 per diluted share, up from $801.0 million ($0.51 per share) in the prior year.
3The company completed the acquisition of i-STAT Corporation for approximately $394 million in January 2004 and announced the acquisition of TheraSense, Inc. for approximately $1.2 billion in April 2004.
4Abbott announced the spin-off of its hospital products business as Hospira, Inc., with a distribution expected on April 30, 2004.
5Operating earnings increased by 5.3% to $1.03 billion, driven by strong sales growth, particularly in Pharmaceuticals and International segments.
6Cash flow from operations significantly increased to $1.36 billion, supporting investments and dividends.
7The company declared a cash dividend of $0.26 per common share, an increase from $0.245 in the prior year.

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions